UNIGE document Scientific Article
previous document  unige:145709  next document
add to browser collection
Title

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

Authors
Frisone, Daniele
Michielin, Olivier
show hidden authors show all authors [1 - 11]
Published in Cancer biology & therapy. 2020, vol. 21, no. 3, p. 197-202
Abstract Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a very rare event, concerning less than 5% of patients.Initial trials with palbociclib in serous ovarian cancer have shown very modest benefit in unselected patient populations, thus underlining the need for a biomarker predicting response. We report the case of a heavily pre-treated patient with a serous ovarian tumor harboring a homozygous deletion of the CDKN2A gene that derived significant, prolonged clinical benefit from palbociclib, a CDK4/6 oral inhibitor, with letrozole. Treatment with palbociclib and letrozole started on February 2018, with an ongoing response after 12 months.In conclusion, homozygous CDKN2A deletion is rare and could be used to predict response to CDK4/6 inhibitors in association with other genomic features. We encourage further trials in this direction.
Identifiers
PMID: 31709901
Full text
Article (Published version) (2.8 MB) - public document Free access
Structures
Research group Lymphomes MALT et réplication virale (807)
Citation
(ISO format)
FRISONE, Daniele et al. Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss. In: Cancer Biology and Therapy, 2020, vol. 21, n° 3, p. 197-202. doi: 10.1080/15384047.2019.1685291 https://archive-ouverte.unige.ch/unige:145709

144 hits

65 downloads

Update

Deposited on : 2020-12-02

Export document
Format :
Citation style :